PYC Therapeutics (ASX:PYC) EBITDA Margin %: 0.00% (As of Dec. 2025)


ASX:PYC PYC Therapeutics Ltd ASX:PYC
35 GF Score
Price A$1.54
! 1 Warning Sign
View Full Analysis

What is PYC Therapeutics EBITDA Margin %?

PYC Therapeutics ASX:PYC 35 EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus rates ASX:PYC with a GF Score™ of 35/100. The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, PYC Therapeutics ranks worse than 105932.1% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. PYC Therapeutics's EBITDA for the six months ended in Dec. 2025 was A$-22.79 Mil. PYC Therapeutics's Revenue for the six months ended in Dec. 2025 was A$0.00 Mil. Therefore, PYC Therapeutics's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.

PYC Therapeutics  (ASX:PYC) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

PYC Therapeutics EBITDA Margin % Related Terms

PYC Therapeutics EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for PYC Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PYC Therapeutics EBITDA Margin % Chart

PYC Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PYC Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:PYC vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, PYC Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PYC Therapeutics EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PYC Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where PYC Therapeutics's EBITDA Margin % falls into.


ASX:PYC
35GF Score
PYC Therapeutics Ltd ASX:PYC
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PYC Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

PYC Therapeutics's EBITDA Margin % for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-50.351/0
= %

PYC Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-22.793/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
PYC Therapeutics (ASX:PYC) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PYC Therapeutics and its competitors. According to the industry distribution chart, PYC Therapeutics ranks #999999 out of 944 companies in the Biotechnology industry.
Is PYC Therapeutics' EBITDA Margin % too high?
PYC Therapeutics' current EBITDA Margin % is 0.00%. Based on the distribution chart, PYC Therapeutics ranks #999999 out of 944 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, PYC Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does PYC Therapeutics' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PYC Therapeutics ranks #999999 out of 944 companies for EBITDA Margin %. This places PYC Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PYC Therapeutics and its competitors. PYC Therapeutics's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PYC Therapeutics stock overvalued right now?
PYC Therapeutics (ASX:PYC) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. PYC Therapeutics' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PYC Therapeutics (ASX:PYC), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PYC Therapeutics Business Description

Other Exchanges PYCXF:USA
Address 6 Verdun Street, Harry Perkins Institute of Medical Research, Nedlands, Perth, WA, AUS, 6009
PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.
35GF Score

Get the complete analysis for ASX:PYC

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.54
Price